Epidemiological survey on the benefit of neuraminidase inhibitors on severe acute respiratory syndrome due to COVID-19

Flores, Thamara Graziela; Gonçalves, Carlos Fernando Antunes; Volpato, Isis Niero; Barbisan, Fernanda; Lampert, Melissa Agostini; Cruz, Ivana Beatrice Manica da; Bonotto, Nathália Cardoso de Afonso.
Rev. epidemiol. controle infecç ; 13(1): 16-21, jan.-mar. 2023. ilus
Artículo en Inglés, Portugués | LILACS | ID: biblio-1512817

Documentos relacionados

  1. In vitro neuraminidase inhibitory concentrations (IC<sub>50</sub>) of four neuraminidase inhibitors in the Japanese 2022-23 season: Comparison with the 2010-11 to 2019-20 seasons.
  2. Comparative effectiveness of neuraminidase inhibitors in patients with influenza: A systematic review and network meta-analysis.
  3. Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza.
  4. Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness.
  5. Low rate of oseltamivir prescription among adults and children with confirmed influenza illness in France during the 2018-19 influenza season.
  6. Antiviral therapies for influenza.
  7. Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants.
  8. Antiviral Treatments for Influenza.
  9. Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014-2019/2020 seasons in Japan: an observational study.
  10. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.